Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Recro Pharma Inc (REPH)

Recro Pharma Inc (REPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Recro Pharma Inc 1 E. UWCHLAN AVE SUITE 112 EXTON PA 19341 USA

www.recropharma.com P: 770-534-8239

Description:

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 117,926
Shares Outstanding, K 56,424
Annual Sales, $ 75,360 K
Annual Net Income, $ -11,370 K
Last Quarter Sales, $ 22,300 K
Last Quarter Net Income, $ -2,360 K
60-Month Beta 1.08
% of Insider Shareholders 14.20%
% of Institutional Shareholders 62.34%
Float, K 48,412
% Float 85.80%

Growth:

1-Year Return -41.46%
3-Year Return -64.33%
5-Year Return -76.09%
5-Year Revenue Growth 8.68%
5-Year Earnings Growth 86.54%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 05/05/22
Earnings Per Share ttm -0.40
EPS Growth vs. Prev Qtr 42.86%
EPS Growth vs. Prev Year 91.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

REPH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -56.66%
Return-on-Assets % -11.14%
Profit Margin % -15.09%
Debt/Equity 2.27
Price/Sales 1.57
Price/Cash Flow N/A
Price/Book 2.33
Book Value/Share 0.90
Interest Coverage -0.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar